A new fight is brewing over the Medicare drug price negotiation program after the Trump administration proposed to consider ...

When blockbuster drugs lose intellectual property protections it can wipe out billions of dollars in revenue for companies ...

Imugene is tapping the market for up to $35 million, while Clever Culture Systems and Compumedics are soaring on positive ...

The participants in the trial – similar to two-thirds of breast cancer patients overall - had tumors that use the hormones ...

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...

The U.S. Food and Drug Administration (FDA) on Thursday published more than 200 complete response letters ((CRLs)), through ...

BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under ...

AstraZeneca spinout Dizal Pharmaceuticals won an FDA accelerated approval for sunvozertinib for previously treated EGFR ex 20 ...

FDA Commissioner Marty Makary said the agency may fast-track new drugs from pharmaceutical companies that “equalize” the cost ...

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth ...

Novartis wins Swiss approval for Coartem Baby, first malaria drug for infants and young children Novartis ( NYSE: NVS) on ...

Digital technology may be on the verge of ‘breaking out’ for schizophrenia treatment, but numerous questions will need to be answered about scalability and costs, experts say.